What does JELY PHARMA do?

JELY PHARMA is a pharmacy in Incourt. Private Limited, started on 19 August 2015, 1 establishment.

What is the address of JELY PHARMA?

The registered office of JELY PHARMA is located at Rue du Jardinier 8 box B, 1315 Incourt.

Is JELY PHARMA still active?

Yes. According to the CBE (30 October 2026) JELY PHARMA is active, legal situation “Normale toestand”, started on 19 August 2015.

Is JELY PHARMA registered on Peppol?

Yes, JELY PHARMA is registered on the Peppol network with ID 0208:0635630013.

What is the enterprise number of JELY PHARMA?

The enterprise number of JELY PHARMA is BE0635630013.

When was JELY PHARMA founded?

JELY PHARMA was founded on 19 August 2015.

Who are the directors of JELY PHARMA?

According to the 2025 annual accounts, the directors of JELY PHARMA are: JULIAN JEHAES.

Is JELY PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 August 2015; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did JELY PHARMA make in 2025?

JELY PHARMA posted a profit after taxes of € 20,540 in financial year 2025.

What is the revenue of JELY PHARMA?

As a small company, JELY PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 253,186.

How much does an employee at JELY PHARMA earn?

The average wage cost per full-time employee at JELY PHARMA was € 72,700 in 2025: staff costs of € 116,246 for 1.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does JELY PHARMA have?

According to the 2025 annual accounts, JELY PHARMA has 1.6 full-time equivalents (FTE).

JELY PHARMA (Private Limited) - Incourt - BE0635630013

Dossier JELY PHARMA, printed on 30 October 2026 from databakkes.be/en/0635630013/jely-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 61 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

JELY PHARMA from Incourt, company number BE0635630013, closed financial year 2025 with a result of € 20,540 after tax. For that financial year JELY PHARMA recorded a gross margin of € 253,186 and equity of € 381. Compared with financial year 2024, the result moved from € 15,299 to € 20,540. Profitable, and profit is growing. The buffer shrank hard: equity is 99 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 1, 2026.

What it is worth Shrank hard

€ 381

▼ 99% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 20,540

▲ 34% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 89,529

▲ 232% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 57,500 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

1.6

▼ 0.3 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 116,246

▼ 19% vs 2024

€ 72,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 60,660

▲ 55% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 282,155

▼ 22% vs 2024

€ 61,238 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 61,292

▲ 19% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 19,993

▲ 99% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 265,376 Gross margin 2022: € 265,376 First fiscal year in the series	€ 245,313 Gross margin 2023: € 245,313 ▼ 8% vs 2022 (€ 265,376) Unfavourable step	€ 233,893 Gross margin 2024: € 233,893 ▼ 5% vs 2023 (€ 245,313) Unfavourable step	€ 253,186 Gross margin 2025: € 253,186 ▲ 8% vs 2024 (€ 233,893) Favourable step	▲ 8%
Profit after taxes	€ 112,018 Profit after taxes 2022: € 112,018 First fiscal year in the series	€ 42,041 Profit after taxes 2023: € 42,041 ▼ 62% vs 2022 (€ 112,018) Unfavourable step	€ 15,299 Profit after taxes 2024: € 15,299 ▼ 64% vs 2023 (€ 42,041) Unfavourable step	€ 20,540 Profit after taxes 2025: € 20,540 ▲ 34% vs 2024 (€ 15,299) Favourable step	▲ 34%
Equity	€ 1 Equity 2022: € 1 First fiscal year in the series	€ 22,042 Equity 2023: € 22,042 ▲ € 22,041 vs 2022 (€ 1) Favourable step	€ 37,341 Equity 2024: € 37,341 ▲ 69% vs 2023 (€ 22,042) Favourable step	€ 381 Equity 2025: € 381 ▼ 99% vs 2024 (€ 37,341) Unfavourable step	▼ 99%
Total debts	€ 661,577 Total debts 2022: € 661,577 First fiscal year in the series	€ 547,500 Total debts 2023: € 547,500 ▼ 17% vs 2022 (€ 661,577) Favourable step	€ 470,294 Total debts 2024: € 470,294 ▼ 14% vs 2023 (€ 547,500) Favourable step	€ 469,303 Total debts 2025: € 469,303 Unchanged (€ 470,294) Favourable step
Cash	€ 184,435 Cash 2022: € 184,435 First fiscal year in the series	€ 96,340 Cash 2023: € 96,340 ▼ 48% vs 2022 (€ 184,435) Unfavourable step	€ 26,990 Cash 2024: € 26,990 ▼ 72% vs 2023 (€ 96,340) Unfavourable step	€ 89,529 Cash 2025: € 89,529 ▲ 232% vs 2024 (€ 26,990) Favourable step	▲ 232%
Land & buildings	€ 120,000 Land & buildings 2022: € 120,000 First fiscal year in the series	€ 110,000 Land & buildings 2023: € 110,000 ▼ 8% vs 2022 (€ 120,000) Unchanged	€ 100,000 Land & buildings 2024: € 100,000 ▼ 9% vs 2023 (€ 110,000) Unchanged	€ 90,000 Land & buildings 2025: € 90,000 ▼ 10% vs 2024 (€ 100,000) Unchanged	▼ 10%
Retained profit	€ 0 Retained profit 2022: € 0 First fiscal year in the series	€ 22,041 Retained profit 2023: € 22,041 Unchanged (€ 0) Favourable step	€ 37,340 Retained profit 2024: € 37,340 ▲ 69% vs 2023 (€ 22,041) Favourable step	€ 380 Retained profit 2025: € 380 ▼ 99% vs 2024 (€ 37,340) Unfavourable step	▼ 99%
Dividend	€ 121,878 Dividend 2022: € 121,878 First fiscal year in the series	€ 20,000 Dividend 2023: € 20,000 ▼ 84% vs 2022 (€ 121,878) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 20,000) Unchanged	€ 57,500 Dividend 2025: € 57,500 Unchanged (€ 0) Unchanged
Bank debt	€ 427,432 Bank debt 2022: € 427,432 First fiscal year in the series	€ 409,909 Bank debt 2023: € 409,909 ▼ 4% vs 2022 (€ 427,432) Favourable step	€ 363,605 Bank debt 2024: € 363,605 ▼ 11% vs 2023 (€ 409,909) Favourable step	€ 282,155 Bank debt 2025: € 282,155 ▼ 22% vs 2024 (€ 363,605) Favourable step	▼ 22%
Balance sheet total	€ 661,578 Balance sheet total 2022: € 661,578 First fiscal year in the series	€ 569,542 Balance sheet total 2023: € 569,542 ▼ 14% vs 2022 (€ 661,578) Unchanged	€ 507,635 Balance sheet total 2024: € 507,635 ▼ 11% vs 2023 (€ 569,542) Unchanged	€ 469,684 Balance sheet total 2025: € 469,684 ▼ 7% vs 2024 (€ 507,635) Unchanged	▼ 7%
Employees (FTE)	1 Employees (FTE) 2022: 1 First fiscal year in the series	1.8 Employees (FTE) 2023: 1.8 ▲ 0.8 vs 2022 (1) Unchanged	1.9 Employees (FTE) 2024: 1.9 ▲ 0.1 vs 2023 (1.8) Unchanged	1.6 Employees (FTE) 2025: 1.6 ▼ 0.3 vs 2024 (1.9) Unchanged	▼ 0.3

Key figures of JELY PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to JELY PHARMA?

What happened at JELY PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 1, 2026 New annual accounts for financial year 2025: profit of € 20,540 (▲ 34% vs 2024). Source: NBB ↗
Aug 19, 2015 New establishment in Schaarbeek. KBO
Aug 19, 2015 Start of the company according to the CBE. KBO
2015 JULIAN JEHAES became a director. NBB

In short

From € 112,018 profit in 2022 to € 20,540 profit in 2025.

Paid € 82,437 in corporate taxes since 2022.

Best year ever: 2022, with € 112,018 profit.

On average € 158,200 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

JULIAN JEHAES

JELY PHARMA

Pharmacie Jehaes-Meiser 100%

Behind JELY PHARMA is JULIAN JEHAES. It owns 100% of Pharmacie Jehaes-Meiser itself.

Directors

According to the 2025 annual accounts

JULIAN JEHAES

Director

since 2015

Establishments

Establishment units

Physical locations of this company

Registered office

Rue du Jardinier 8 box B

1315 Incourt

2.245.046.786

Rogierlaan 407

1030 Schaarbeek

Active since 19 August 2015

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

ERGONLINE

€ 40,989 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0635.630.013
VAT number: BE 0635.630.013
Registered office: Rue du Jardinier 8 bus B, 1315 Incourt
Names & denominations: JELY PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 19 August 2015
Peppol: Active · Active since 16 Apr 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗